Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 1671 to 1680 of 1911 total matches.

A New Snake Antivenom

   
The Medical Letter on Drugs and Therapeutics • Jun 25, 2001  (Issue 1107)
the package insert states that the antivenom should be refrigerated, it has been safe after 60 days’ exposure ...
CroFab, an antigen-binding-fragment (Fab) antivenom of ovine origin, has been approved by the FDA for treatment of North American rattlesnake envenomation.
Med Lett Drugs Ther. 2001 Jun 25;43(1107):55-6 |  Show IntroductionHide Introduction

Drug-eluting Stents

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 2003  (Issue 1152)
(PW Serruys et al, Circulation 2002; 106:798). The long-term effects of a 30-day local exposure ...
Most angioplasty procedures for coronary artery disease now include placement of stents, which have improved both short- and long-term success rates. The main limitation is restenosis, which occurs in about 25% of patients. Drug-eluting stents intended to reduce the incidence of restenosis have been approved for use in Europe, but not yet in the US.
Med Lett Drugs Ther. 2003 Mar 17;45(1152):23-4 |  Show IntroductionHide Introduction

Olanzapine/Fluoxetine (Symbyax) for Bipolar Depression

   
The Medical Letter on Drugs and Therapeutics • Mar 15, 2004  (Issue 1178)
with fluoxetine (in doses of 6 and 25 mg, 6 and 50 mg, or 12 and 50 mg per day) in a flexible dosing schedule ...
The fixed-dose combination of olanzapine and fluoxetine (Symbyax - Lilly) has been approved by the FDA for treatment of depressive episodes associated with bipolar disorder. Olanzapine alone (Zyprexa), which is mainly used as an antipsychotic (Medical Letter 2003; 45:102), is FDA-approved for treatment of acute manic episodes and for maintenance treatment of bipolar disorder. Fluoxetine alone (Prozac, and others), which is mainly used as an antidepressant (Medical Letter 2003; 45:93), has no specific approval for use in bipolar...
Med Lett Drugs Ther. 2004 Mar 15;46(1178):23-4 |  Show IntroductionHide Introduction

Botulinum Toxin (Botox) for Axillary Hyperhidrosis

   
The Medical Letter on Drugs and Therapeutics • Sep 13, 2004  (Issue 1191)
% of those injected with placebo. The median duration of the response was 201 days. 2 ADVERSE EFFECTS ...
Botulinum toxin type A (Botox - Allergan) has been approved by the FDA for treatment of severe underarm sweating ("primary axillary hyperhidrosis"). Injected into the skin, botulinum toxin decreases sweating by causing chemical denervation of the sweat gland.
Med Lett Drugs Ther. 2004 Sep 13;46(1191):76 |  Show IntroductionHide Introduction

In Brief: Melamine

   
The Medical Letter on Drugs and Therapeutics • Oct 20, 2008  (Issue 1297)
from studies in rats, a tolerable daily intake of 0.63 mg/kg/day. 1 However, the combination of melamine ...
Melamine present in infant formula and other milk products has been associated with widespread illness and some deaths among infants in China. It was also identified in pet food sold in North America after a large number of pets became ill and some died. In both the infants and the pets, renal injury appeared to be the cause.1Melamine (C3H6N6) is a heterocyclic compound, two-thirds nitrogen by weight, that is slightly soluble in water. When combined with formaldehyde, it forms melamine resin, which has a wide variety of industrial applications including the manufacturing of kitchenware,...
Med Lett Drugs Ther. 2008 Oct 20;50(1297):81 |  Show IntroductionHide Introduction

In Brief: Different Diets

   
The Medical Letter on Drugs and Therapeutics • Mar 23, 2009  (Issue 1308)
of 750 kcal per day. Most participants lost weight in the first 6 months and regained some thereafter ...
A recent article in the New England Journal of Medicine confirms something that others, including The Medical Letter (Treat Guidel Med Lett 2008; 6:23), have been saying for years: no particular combination of protein, carbohydrate and fat in the diet offers any advantage in losing weight. This randomized 2-year trial followed 800 overweight and obese subjects on low fat/average protein, low fat/high protein, high fat/average protein, and high fat/high protein diets. Carbohydrate intake varied from 35% (in the high fat/high protein diet) to 65% (in the low fat/average protein diet). All...
Med Lett Drugs Ther. 2009 Mar 23;51(1308):24 |  Show IntroductionHide Introduction

PDE5 Inhibitors for Erectile Dysfunction

   
The Medical Letter on Drugs and Therapeutics • Feb 06, 2012  (Issue 1383)
day. 2. Patients should be on stable alpha-blocker therapy before starting treatment with a PDE5 ...
Sildenafil (Viagra), tadalafil (Cialis) and vardenafil (Levitra, Staxyn) have become the standard treatment for erectile dysfunction. Head-to-head comparisons of these agents are still lacking, but some differences between them and new recommendations for their dosing (see Table 2) are worth noting.
Med Lett Drugs Ther. 2012 Feb 6;54(1383):10-1 |  Show IntroductionHide Introduction

Bupivacaine Liposome Injection (Exparel) for Postsurgical Pain

   
The Medical Letter on Drugs and Therapeutics • Apr 02, 2012  (Issue 1387)
instillation of short-acting bupivacaine into the surgical site (over 2-5 days) using a wound-based catheter ...
The FDA has approved a new formulation (Exparel – Pacira) of the local anesthetic bupivacaine (Marcaine, and others) for use in the management of postsurgical pain in adults.
Med Lett Drugs Ther. 2012 Apr 2;54(1387):26-7 |  Show IntroductionHide Introduction

Fentanyl Sublingual Spray (Subsys) for Breakthrough Cancer Pain

   
The Medical Letter on Drugs and Therapeutics • May 14, 2012  (Issue 1390)
therapy (taking >60 mg/day of oral morphine or the equivalent). Fentanyl is already available ...
The FDA has approved a sublingual spray formulation of fentanyl (Subsys – Insys) for management of breakthrough pain in adult cancer patients who are receiving and are tolerant to opioid therapy (taking ≥60 mg/day of oral morphine or the equivalent). Fentanyl is already available in the US for intravenous, intrathecal, epidural, transdermal and transmucosal use.
Med Lett Drugs Ther. 2012 May 14;54(1390):39-40 |  Show IntroductionHide Introduction

Axitinib (Inlyta) for Advanced Renal Cell Carcinoma

   
The Medical Letter on Drugs and Therapeutics • Jun 11, 2012  (Issue 1392)
alfa 1. Wholesale acquisition cost (WAC) for 30 days' treatment. Source: PricePointRx™. Reprinted ...
Axitinib (Inlyta – Pfizer), an oral tyrosine kinase inhibitor, has been approved by the FDA for treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. It is the fourth oral tyrosine kinase inhibitor to be approved for treatment of advanced renal cell carcinoma.
Med Lett Drugs Ther. 2012 Jun 11;54(1392):47-8 |  Show IntroductionHide Introduction